García-Delpech, SalvadorUdaondo, PatriciaFernández-Santodomingo, Alex SamirGarcía-Teillard, Damian2023-05-032023-05-032022-08-311663-2699http://hdl.handle.net/10668/20194The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks. It was initiated upon refractoriness to prior conventional topical treatment. Visual acuity, corneal sensitivity test at four corneal quadrants, fluorescein staining, OC,T and photography were performed weekly during 9 weeks of follow-up from the completion of treatment. At the ninth week of follow-up, corneal sensitivity improvement and healing of corneal ulcers were found in all patients. No adverse events were reported, and no corneal ulcer recurrence was observed over a 4-year follow-up period. Cenegermin should be used in combination with conventional therapy for advanced NK, as it is an effective treatment for healing corneal ulcers, improving the corneal surface homeostasis and avoiding surgery.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/CenegerminNeurotrophic keratopathyRecombinant human nerve growth factorresearch article36160492open access10.1159/000525923PMC9459538https://www.karger.com/Article/Pdf/525923https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459538/pdf